Based on the Office for National Statistics population and the NHS Quality and Outcomes framework 2023-24 around 614,000 adults in England have heart failure. Of these, around 63% (387,000) adults are ...

Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS. These ...

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

Our independent appraisal committee has approved the use of gene editing therapy exagamglogene autotemcel (exa-cel) for use in the NHS in England, providing a potential cure for some people with ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary ...

NICE helps the NHS and wider health and care system deliver the best care to people, fast, while ensuring value for the taxpayer. We do this by developing guidance, advice and information through a ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19. The government, the NHS or the UK Health Security Agency may choose to use ...